Lupin Pharmaceuticals gets FDA approval for SOLOSEC sNDA
Lupin Pharmaceuticals has secured approval from the US Food and Drug Administration for its supplemental new drug application (sNDA) to expand the indication of SOLOSEC ... Read More
Lupin Pharmaceuticals signs agreement with Exeltis to promote Solosec in US
Indian pharma company Lupin Pharmaceuticals has signed an agreement with Exeltis USA to promote its antimicrobial drug Solosec (secnidazole) in the US market. Solosec is ... Read More
Lupin expands US women’s health portfolio with $150m acquisition of Symbiomix Therapeutics
Lupin Limited, a Mumbai-based generics pharmaceutical company, has strategically broadened its foothold in the women’s health sector by acquiring Symbiomix Therapeutics. The acquisition, valued at ... Read More